Addex Therapeutics Ltd (NASDAQ:ADXN) Sees Significant Decline in Short Interest

Addex Therapeutics Ltd (NASDAQ:ADXN) was the target of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 1,500 shares, a decline of 54.5% from the January 15th total of 3,300 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily volume of 37,400 shares, the short-interest ratio is currently 0.0 days.

Addex Therapeutics Trading Up 4.1 %

Addex Therapeutics stock opened at $7.01 on Thursday. Addex Therapeutics has a 12-month low of $6.73 and a 12-month high of $27.90. The stock has a market cap of $7.43 million, a P/E ratio of -20.60 and a beta of 1.77. The company has a fifty day simple moving average of $7.77 and a 200-day simple moving average of $8.83.

Addex Therapeutics (NASDAQ:ADXN) last announced its quarterly earnings results on Friday, November 22nd. The company reported ($2.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.40) by ($1.37). Addex Therapeutics had a net margin of 850.30% and a negative return on equity of 112.43%.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.